Naproxen Could Serve As NSAID Safety Trial Standard, Advisory Panel Says
This article was originally published in The Tan Sheet
Executive Summary
Naproxen should be excluded from any cardiovascular warnings required for NSAIDs, FDA's joint panel on COX-2 safety recommended Feb. 18